


Encenicline hydrochloride

Chemical Properties

CAS No. :	550999-74-1
Formula:	C ₁₆ H ₁₇ ClN ₂ O ₂ ·HCl
Molecular Weight:	357.3
Storage:	Powder: -20°C for 3 years In solvent: -80°C for 1 year Actual storage temperature shall be subject to the COA.



Biological Description

Description	Encenicline hydrochloride (EVP-6124 hydrochloride) is a novel partial agonist of $\alpha 7$ neuronal nicotinic acetylcholine receptors (nAChRs).
Targets(IC50)	AChR
In vitro	EVP-6124 hydrochloride displaces [3H]-MLA (Methyllycaconitine) ($K_i=9.98$ nM, $pIC_{50}=7.65\pm 0.06$, $n=3$) and [125I]- α -bungarotoxin ($K_i=4.33$ nM, $pIC_{50}=8.07\pm 0.04$, $n=3$). EVP-6124 is approximately 300 fold more potent than the natural agonist ACh ($K_i=3$ μ M), measured in binding assays using [3H]-MLA. EVP-6124 inhibits the 5-HT ₃ receptor by 51% at 10 nM, the lowest concentration tested. Evaluation of the human 5-HT _{2B} receptor expressed in CHO cells demonstrates displacement of [3H]-mesulergine ($K_i=14$ nM) and only antagonist activity in the rat gastric fundus assay at an IC ₅₀ of 16 μ M. In binding and functional experiments, EVP-6124 shows selectivity for $\alpha 7$ nAChRs and does not activate or inhibit heteromeric $\alpha 4\beta 2$ nAChRs[1].
In vivo	EVP-6124 hydrochloride demonstrates effective brain penetration and sufficient exposure duration, showing significant memory restoration at a dose of 0.3 mg/kg orally in scopolamine-induced memory impairment in rats, measured by an object recognition task (ORT). When combined with donepezil at sub-eficacious doses (0.1 mg/kg, orally for donepezil and 0.03 mg/kg, orally for EVP-6124), full memory restoration is achieved, suggesting synergistic effects. In a 24-hour retention natural forgetting test, EVP-6124 at 0.3 mg/kg orally enhances memory, an effect inhibited by the selective $\alpha 7$ nAChR antagonist methyllycaconitine, validating the involvement of $\alpha 7$ nAChR in the mechanism of action. EVP-6124 binds to rat plasma proteins at a moderate level with a fractional unbound average of 11% and shows dose-proportional pharmacokinetics over a 0.1-30 mg/kg oral dose range. Peak times (T_{max}) are recorded at 4 hours in plasma and 2 hours in the brain, with brain concentrations maintaining from 2 to 8 hours, and brain-to-plasma (B:P) ratios ranging from 1.7 to 5.1. Additionally, at a dose of 0.4 mg/kg intraperitoneally, EVP-6124 achieves peak brain concentration in 2 hours, maintaining effective levels for at least 4 hours, and notably increases NMDAR saturation index in wild-type mice without affecting wakefulness or locomotion.
Kinase Assay	Binding or activity of EVP-6124 is measured at 10 μ M in a selectivity panel according to standard validated protocols under conditions defined by the contractor. For the 5-HT _{2A} receptor binding assay, membranes are prepared from HEK293 cells expressing the human recombinant 5-HT _{2A} receptor. For 5-HT _{2B} and 5-HT _{2C} receptor binding assays,

Kinase Assay	membranes are prepared from CHO cells expressing the human recombinant 5-HT2B or 5-HT2C receptor. Affinity is determined by incubating different concentrations of EVP-6124 in binding buffer for 1 h. For 5-HT2A binding, the incubation is at 22°C in the presence of 0.5 nM [3H]-ketanserin; for 5-HT2B, at 22°C in the presence of 2 nM [3H]-mesulergine; and for 5-HT2C, at 37°C in the presence of 1 nM [3H]-mesulergine. Nonspecific binding is determined in the presence of 1 µM ketanserin, 10 µM mesulergine, or 10 µM RS-102221 for 5-HT2A, 5-HT2B, or 5-HT2C, respectively. All measurements are performed in triplicate. EVP-6124 is also tested in the 5-HT2B rat gastric fundus tissue response assay. Briefly, inhibition of α-methyl serotonin-induced contraction is isometrically measured. All measurements are performed in duplicate[1].
--------------	---

Solubility Information

Solubility	DMSO: 10 mg/mL (27.99 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween 80+45% Saline: 1 mg/mL (2.8 mM),Sonication is recommended. <i>Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.</i>

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.7988 mL	13.9938 mL	27.9877 mL
5 mM	0.5598 mL	2.7988 mL	5.5975 mL
10 mM	0.2799 mL	1.3994 mL	2.7988 mL
50 mM	0.056 mL	0.2799 mL	0.5598 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Prickaerts, J., van Goethem, N., Chesworth, R., Shapiro, G., Boess, F., & Methfessel, C. et al. (2012). EVP-6124, a novel and selective α7 nicotinic acetylcholine receptor partial agonist, improves memory performance by potentiating the acetylcholine response of α7 nicotinic acetylcholine receptors. *Neuropharmacology*, 62(2), 1099-1110. doi: 10.1016/j.neuropharm.2011.10.024

Thomas Papouin, et al. Septal Cholinergic Neuromodulation Tunes the Astrocyte-Dependent Gating of Hippocampal NMDA Receptors to Wakefulness. *Neuron*. 2017 May 17;94:1-15.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481